Form 4: Zeo ScientifiX CMO Granted 175,000 Restricted Shares

Zeo ScientifiX's Chief Medical Officer, George Craig Shapiro, was granted 175,000 restricted common shares under the company's 2021 Equity Incentive Plan.

Summary

• George Craig Shapiro, Chief Medical Officer and Director of Zeo ScientifiX, Inc. (ZEOX), acquired 175,000 shares of common stock.
• The acquisition occurred on January 14, 2026, and represents a grant of restricted shares under the company's 2021 Equity Incentive Plan.
• The shares were acquired at a price of $0 per share.
• Following this transaction, George Craig Shapiro beneficially owns a total of 578,021 shares of common stock.
• The restricted shares will vest in two tranches: 50% on the 8th month anniversary of the grant date and the remaining 50% on the 12th month anniversary.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 6

Explanation: The grant of restricted shares to a key executive is generally a neutral to slightly positive event, as it aligns management incentives with shareholder interests, though it does not directly impact immediate financial performance or operational outlook.

Positives

• The grant of restricted shares to a key executive like the Chief Medical Officer aligns management's interests with those of shareholders, incentivizing long-term performance.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned equity compensation strategy.

Future Outlook

The vesting schedule for the restricted shares indicates a future increase in George Craig Shapiro's vested ownership, contingent on continued employment and performance, aligning his long-term interests with the company's success.

Industry Context

Equity grants to executive officers are a standard practice across industries, particularly in the biotechnology and scientific sectors, to attract, retain, and motivate key talent. This grant is consistent with typical executive compensation structures aimed at aligning leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The use of a 2021 Equity Incentive Plan for restricted share grants is a common mechanism for executive compensation, comparable to practices at other publicly traded companies in the biotech and pharmaceutical sectors.
• The vesting schedule (50% at 8 months, 50% at 12 months) is relatively short-term compared to typical multi-year vesting schedules (e.g., 3-4 years) often seen for larger equity grants in established companies, which might suggest a specific retention or performance incentive for this particular grant.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant from Zeo ScientifiX, Inc. to its Chief Medical Officer and Director, George Craig Shapiro, which is an insider transaction.

Stakeholder Impact

• Shareholders: The grant represents a form of executive compensation, potentially leading to minor dilution over time as shares vest, but also aims to align management's interests with shareholder value creation.
• Employees: The use of an equity incentive plan can signal a commitment to performance-based compensation, potentially impacting employee morale and retention strategies.

Next Steps

• The restricted shares will vest according to the specified schedule: 50% on September 14, 2026, and the remaining 50% on January 14, 2027.

Key Dates

Keywords

Zeo ScientifiX, ZEOX, Form 4, Insider Transaction, Restricted Stock Grant, Equity Incentive Plan, George Craig Shapiro, Chief Medical Officer, Director